Design and rationale of the EMPA‐VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure

AIMS: Despite substantial improvements over the last three decades, heart failure (HF) remains associated with a poor prognosis. The sodium‐glucose co‐transporter‐2 inhibitor empagliflozin demonstrated significant reductions of HF hospitalization in patients with HF independent of the presence or ab...

Descripción completa

Detalles Bibliográficos
Autores principales: Hundertmark, Moritz J., Agbaje, Olorunsola F., Coleman, Ruth, George, Jyothis T., Grempler, Rolf, Holman, Rury R., Lamlum, Hanan, Lee, Jisoo, Milton, Joanne E., Niessen, Heiko G., Rider, Oliver, Rodgers, Christopher T., Valkovič, Ladislav, Wicks, Eleanor, Mahmod, Masliza, Neubauer, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Study Designs
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318430/
https://www.ncbi.nlm.nih.gov/pubmed/33960149
http://dx.doi.org/10.1002/ehf2.13406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318430/
https://www.ncbi.nlm.nih.gov/pubmed/33960149
http://dx.doi.org/10.1002/ehf2.13406

Ejemplares similares